Savara(US:SVRA) Globenewswire·2025-10-17 20:52Core Viewpoint - A class action has been filed against Savara Inc. for allegedly misleading investors regarding the viability of its lead drug candidate, MOLBREEVI, during a specified period [1][3]. Group 1: Allegations - The complaint states that Savara failed to disclose critical information about the MOLBREEVI Biologics License Application (BLA), including insufficient data on chemistry, manufacturing, and controls [3]. - It is alleged that the FDA was unlikely to approve the MOLBREEVI BLA in its current form, which would delay the submission timeline previously communicated to investors [3]. - The delay in regulatory approval raised concerns about the company's need to raise additional capital [3]. Group 2: Impact on Stock Price - Following the announcement of a refusal to file (RTF) letter from the FDA regarding the MOLBREEVI BLA, Savara's stock price dropped by $0.90, or 31.69%, closing at $1.94 per share on May 27, 2025 [4]. Group 3: Class Action Participation - Shareholders interested in participating as lead plaintiffs in the class action must submit their papers by November 7, 2025 [5]. - Shareholders can remain absent class members if they choose not to participate in the case [5].